Celltrion Pharm Stock Working Capital

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

In accordance with the company's disclosures, Celltrion Pharm has a Working Capital of 58.94 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all Republic of Korea stocks is notably lower than that of the firm.

The Macroaxis Fundamental Analysis modules help investors analyze Celltrion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celltrion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celltrion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.